STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024)

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) announces its participation in the upcoming Stephens Annual Investment Conference in Nashville. Chief Financial Officer Patrick F. Williams will participate in a webcast fireside chat on Wednesday, November 20, 2024, at 11:00 a.m. ET. STAAR Surgical, with over 40 years in ophthalmic surgery, specializes in developing implantable lenses, particularly the EVO ICL™ product line for myopia, astigmatism, and presbyopia. The company has sold more than 3,000,000 ICLs across 75+ countries and operates manufacturing facilities in California and Switzerland.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be held in Nashville, TN.

Event: Stephens Annual Investment Conference (NASH2024)
Management Attendee: Patrick F. Williams, Chief Financial Officer
Date: Wednesday, November 20, 2024
Time: 11:00 a.m. ET / 8:00 a.m. PT
Location: Live Webcast

The live webcast link includes an option to pre-register. An online replay of the webcast will also be available on STAAR’s investor website at https://investors.staar.com/.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113681040/en/

Investors & Media

Brian Moore

Vice President, Investor Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Connie Johnson

Director, Investor Relations and HPMS

(626) 303-7902, Ext. 2207

cjohnson@staar.com

Source: STAAR Surgical Company

FAQ

When is STAAR Surgical (STAA) presenting at the Stephens Annual Investment Conference 2024?

STAAR Surgical will present on Wednesday, November 20, 2024, at 11:00 a.m. ET / 8:00 a.m. PT.

How many ICL lenses has STAAR Surgical (STAA) sold globally?

STAAR Surgical has sold more than 3,000,000 ICLs to date, marketing these lenses in over 75 countries.

Where are STAAR Surgical's (STAA) manufacturing facilities located?

STAAR Surgical operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA, and Nidau, Switzerland.

What types of eye conditions does STAAR Surgical's (STAA) EVO ICL treat?

STAAR Surgical's EVO ICL treats myopia, astigmatism, and presbyopia.